Skip to the content
Aresma PartnersAresma Partners
Corporate Finance and M&A Advisory Services
  • Approach
  • M&A and Financial Advisory
  • How
  • Contact us
  • Approach
  • M&A and Financial Advisory
  • How
  • Contact us

Author: AresmaPartner

RSS CSRwire Press Releases, Events and Reports

  • Webster Bank Corporate Responsibility Report: Office of Corporate Responsibility June 8, 2023
    In 2022, Webster’s merger with Sterling National Bank increased our capabilities and scale, allowing us to build on both companies’ long-standing records of citizenship, sustainability and responsibility.

RSS TechCrunch

  • GM follows Ford’s lead and adopts Tesla chargers June 8, 2023
    General Motors will integrate Tesla’s electric vehicle charging standard in its future EVs, CEO Mary Barra said Thursday during a Twitter Spaces with Tesla CEO Elon Musk. The agreement between the erstwhile rivals comes less than two weeks after Ford announced a similar partnership, and signals that other automakers could soon follow. As with the […]
  • ‘The Witcher’ Season 3 drops full trailer June 8, 2023
    The full trailer for “The Witcher” season three was released on Thursday, giving viewers a taste of what to expect in the next installment of the hit Netflix series. In the new trailer, Geralt continues his mission to protect Ciri from monsters, monarchs, mages and anyone else who wants to capture her. We also see […]

RSS VentureBeat

  • Path of Exile 2 teases announcement for July 28 at SGF June 8, 2023
    Grinding Gear Games teased more info on Path of Exile 2 at Summer Games Fest. More information is expected in July.

RSS Biotech Finances

  • Innate pharma, Sanofi, SMAIO, Pherecydes Pharma June 8, 2023
    La FDA accorde un statut Fast Track au SAR’579 / IPH6101 dans le traitement de maladies hématologiques. Ce candidat-médicament est un NK Cell Engager trifonctionnel anti-CD123 engageant les récepteurs NKp46 et CD16. Issu d’une collaboration de recherche entre Innate Pharma et Sanofi, il est aujourd’hui développé par le groupe pharmaceutique français. La medtech française SMAIO […]
  • Theranexus June 7, 2023
    Theranexus (ALTHX) et la Fondation Beyond Batten Disease (BBDF) obtiennent l’avis positif de l’Agence européenne des médicaments sur le design de l’étude pivot de phase 3 de leur candidat médicament Batten-1. La réponse de l’EMA est alignée celle de la FDA début mai 2023. Les mêmes critères d’efficacité ont été retenus. La population cible sera composée d’environ 60 patients CLN3 âgés de 4 à 16 ans, dont la randomisation sera […]
Aresma Partners, 10/35 Howard St, Brisbane City QLD 4000, Australia Australia Contact - 594 a chemin du quartier d'Espagne, 30900 Nimes, Languedoc-Roussillon, Occitanie, France Contact France
To the top ↑ Up ↑
  • France
  • United Kingdom
  • Australia